{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:56:18Z","timestamp":1794491778677,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish GELTAMO Foundation"},{"name":"Takeda"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1093\/annonc\/mdz009","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T05:40:35Z","timestamp":1547530835000},"page":"612-620","source":"Crossref","is-referenced-by-count":119,"title":["Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)"],"prefix":"10.1016","volume":"30","author":[{"given":"R.","family":"Garcia-Sanz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"de la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Pinana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sanchez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Rodriguez-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jimenez-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1093\/annonc\/mdz009_bb0010","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz009_bb0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/asheducation-2016.1.331","article-title":"Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma","volume":"2016","author":"Moskowitz","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1093\/annonc\/mdz009_bb0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"8852","key":"10.1093\/annonc\/mdz009_bb0025","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"10.1093\/annonc\/mdz009_bb0030","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1093\/annonc\/mdz009_bb0035","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V81.5.1137.1137","article-title":"The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients","volume":"81","author":"Chopra","year":"1993","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdz009_bb0040","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","article-title":"Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas\/Transplante Autologo de Medula Osea Spanish Cooperative Group","volume":"19","author":"Sureda","year":"2001","journal-title":"JCO"},{"issue":"6","key":"10.1093\/annonc\/mdz009_bb0045","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cncr.23715","article-title":"High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience","volume":"113","author":"Gopal","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdz009_bb0050","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1200\/JCO.1993.11.12.2351","article-title":"One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome","volume":"11","author":"Rapoport","year":"1993","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz009_bb0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/A:1008283909959","article-title":"Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)","volume":"9","author":"Josting","year":"1998","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz009_bb0060","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00277-014-2114-0","article-title":"ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma","volume":"93","author":"Labrador","year":"2014","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1093\/annonc\/mdz009_bb0065","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.14133","article-title":"Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy","volume":"174","author":"Martinez","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1093\/annonc\/mdz009_bb0070","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"issue":"27","key":"10.1093\/annonc\/mdz009_bb0075","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory hodgkin lymphoma: final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz009_bb0080","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1026454831340","article-title":"ESHAP is an active regimen for relapsing Hodgkin's disease","volume":"10","author":"Aparicio","year":"1999","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz009_bb0085","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1093\/annonc\/mdz009_bb0090","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9980","key":"10.1093\/annonc\/mdz009_bb0095","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1093\/annonc\/mdz009_bb0100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz009_bb0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1093\/annonc\/mdz009_bb0110","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin Lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1093\/annonc\/mdz009_bb0115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz009_bb0120","first-page":"5","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz009_bb0125","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"issue":"15","key":"10.1093\/annonc\/mdz009_bb0130","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1093\/annonc\/mdz009_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"5\u20136","key":"10.1093\/annonc\/mdz009_bb0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428199909058458","article-title":"Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients","volume":"33","author":"Soussain","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1093\/annonc\/mdz009_bb0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdz009_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O'Connor","year":"2018","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdz009_bb0155","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1093\/annonc\/mdz009_bb0160","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","article-title":"How I treat relapsed and refractory Hodgkin lymphoma","volume":"117","author":"Kuruvilla","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1093\/annonc\/mdz009_bb0165","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1093\/annonc\/mdz009_bb0170","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1093\/annonc\/mdz009_bb0175","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00277-011-1209-0","article-title":"Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival","volume":"90","author":"Sucak","year":"2011","journal-title":"Ann Hematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/4\/612\/28564927\/mdz009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:55:31Z","timestamp":1624697731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419311081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0923753419311081"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz009","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}